Despite preclinical success of inhibiting HSF-1 in in vitro assays and successful demonstration of retardation of tumor growth in small animal models, each of the inhibitors listed above has limitations in translation into a drug for clinical use. This evidence concerns the gene HSF1 and neoplasm.